YU76902A - Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove koombinacije lekova - Google Patents

Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove koombinacije lekova

Info

Publication number
YU76902A
YU76902A YU76902A YUP76902A YU76902A YU 76902 A YU76902 A YU 76902A YU 76902 A YU76902 A YU 76902A YU P76902 A YUP76902 A YU P76902A YU 76902 A YU76902 A YU 76902A
Authority
YU
Yugoslavia
Prior art keywords
hypertrophy
diseases associated
treatment
substances
myocardial diseases
Prior art date
Application number
YU76902A
Other languages
English (en)
Inventor
Jurgen Dammgen
Brian Guth
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority to MEP-459/08A priority Critical patent/MEP45908A/xx
Publication of YU76902A publication Critical patent/YU76902A/sh
Publication of RS51478B publication Critical patent/RS51478B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pronalazak se odnosi na novu primenu bradikardijskih supstanci, kao što su blokatori Ca++ kanala, blokatori beta-receptora ili blokatori if -kanala, pri čemu prednost imaju blokatori if -kanala, u datom slučaju, u kombinaciji sa kardioaktivnom supstancom, radi indukovanja regresije miokardnih oboljenja povezanih sa hipertrofijom, naročito za lečenje idiopatskih, hipertrofičnih kardiomiopatija (HCM), kod čoveka i domaće životinje.[The invention relates to a novel use of bradycardiac substances such as a Ca++ channel blocker, beta-receptor blockers or if channel blockers, the if channel blockers being preferred. Said substances are optionally used in combination with a cardio-active substance for inducing the regression of myocardial diseases associated with hypertrophy, in particular for treating ideopathic hypertrophic cardiomyopathies (HCM) in humans and domestic animals.
YUP-769/02A 2000-04-13 2001-04-07 Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova RS51478B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-459/08A MEP45908A (en) 2000-04-13 2001-04-07 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (2)

Publication Number Publication Date
YU76902A true YU76902A (sh) 2006-05-25
RS51478B RS51478B (sr) 2011-04-30

Family

ID=7638652

Country Status (33)

Country Link
US (2) US7208508B2 (sh)
EP (2) EP1276476B1 (sh)
JP (1) JP3905386B2 (sh)
KR (1) KR20020089453A (sh)
CN (1) CN1245963C (sh)
AT (1) ATE330588T1 (sh)
AU (2) AU2001270484B2 (sh)
BG (1) BG65816B1 (sh)
BR (1) BR0109996A (sh)
CA (2) CA2575059A1 (sh)
CY (1) CY1105081T1 (sh)
CZ (1) CZ300549B6 (sh)
DE (2) DE10018401A1 (sh)
DK (1) DK1276476T3 (sh)
EA (1) EA006977B1 (sh)
EE (1) EE05099B1 (sh)
ES (1) ES2266216T3 (sh)
HR (1) HRP20020815A2 (sh)
HU (1) HU228387B1 (sh)
IL (2) IL152103A0 (sh)
ME (1) MEP45908A (sh)
MX (1) MXPA02009935A (sh)
NO (1) NO330311B1 (sh)
NZ (1) NZ521934A (sh)
PL (1) PL215235B1 (sh)
PT (1) PT1276476E (sh)
RS (1) RS51478B (sh)
SI (1) SI1276476T1 (sh)
SK (1) SK286075B6 (sh)
TR (1) TR200202326T2 (sh)
UA (1) UA78679C2 (sh)
WO (1) WO2001078699A2 (sh)
ZA (1) ZA200208162B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
KR101194453B1 (ko) * 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
CN101247832B (zh) * 2005-06-27 2011-12-28 第一三共株式会社 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2432452B1 (de) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Pharmazeutische telmisartan-trinklösung
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
JP2014521714A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ネコ科動物の心不全を治療および予防する方法において使用するための奇異性電流（Ｉｆ）阻害薬
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts
JP7050893B2 (ja) 2017-07-07 2022-04-08 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
CN1135757A (zh) * 1993-09-24 1996-11-13 普罗克特和甘保尔公司 新型含脱氧和氧被取代的糖的14-氨基类固醇
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
SG142116A1 (en) * 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
TR200202326T2 (tr) 2003-03-21
KR20020089453A (ko) 2002-11-29
AU2001270484B2 (en) 2007-01-25
DE50110262D1 (de) 2006-08-03
US20070155679A1 (en) 2007-07-05
DE10018401A1 (de) 2001-10-25
EA006977B1 (ru) 2006-06-30
ATE330588T1 (de) 2006-07-15
CZ20023752A3 (cs) 2003-03-12
NO330311B1 (no) 2011-03-28
CA2575059A1 (en) 2001-10-25
PT1276476E (pt) 2006-09-29
MEP45908A (en) 2011-02-10
CA2404120C (en) 2008-01-22
SI1276476T1 (sl) 2006-10-31
BG107103A (bg) 2003-04-30
CZ300549B6 (cs) 2009-06-10
ES2266216T3 (es) 2007-03-01
RS51478B (sr) 2011-04-30
CN1422153A (zh) 2003-06-04
CN1245963C (zh) 2006-03-22
IL152103A (en) 2008-07-08
WO2001078699A2 (de) 2001-10-25
BR0109996A (pt) 2003-05-27
SK286075B6 (sk) 2008-03-05
HU228387B1 (en) 2013-03-28
EE200200590A (et) 2004-04-15
NO20024924D0 (no) 2002-10-11
UA78679C2 (en) 2007-04-25
WO2001078699A3 (de) 2002-06-20
EP1276476B1 (de) 2006-06-21
EA200201053A1 (ru) 2003-02-27
EP1276476A2 (de) 2003-01-22
PL357827A1 (en) 2004-07-26
US7208508B2 (en) 2007-04-24
EP1666042A3 (de) 2006-06-21
ZA200208162B (en) 2003-10-17
HUP0300917A2 (hu) 2003-08-28
PL215235B1 (pl) 2013-11-29
MXPA02009935A (es) 2003-02-12
AU7048401A (en) 2001-10-30
HRP20020815A2 (en) 2004-12-31
NO20024924L (no) 2002-10-11
HUP0300917A3 (en) 2009-04-28
DK1276476T3 (da) 2006-08-14
IL152103A0 (en) 2003-07-31
CY1105081T1 (el) 2009-11-04
US20040014795A1 (en) 2004-01-22
SK14582002A3 (sk) 2003-03-04
EE05099B1 (et) 2008-12-15
CA2404120A1 (en) 2001-10-25
JP3905386B2 (ja) 2007-04-18
BG65816B1 (bg) 2010-01-29
NZ521934A (en) 2007-05-31
EP1666042A2 (de) 2006-06-07
JP2003535050A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
YU76902A (sh) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove koombinacije lekova
MXPA02011897A (es) Combinaciones y composiciones que interfieren con vegf/receptor de vegf y la funcion de angiopoyetina/tie y su uso (ii).
BR0016681B1 (pt) composição amaciante de tecidos, e, método de tratamento de tecido.
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
IL189629A0 (en) Compositions containing human ctla-4 antibodies
TW200701977A (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
AU2003301185A1 (en) Treatment of fabrics, fibers, or yarns
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
MX233159B (es) Composiciones para tratamientos de telas.
WO2003075953A3 (en) Immunomodulatory polymeric antigens for treating inflammatory pathogies
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
DE60021360D1 (de) Vegf angiogenische wachstumsfaktoren zur behandlung von peripheren neuropathie
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
ATE333277T1 (de) Behandlung von dyskinesie
DE60105053D1 (de) Zusammensetzungen zur behandlung von gewebe
EP1372648A4 (en) KIEASE TIE2 RECEPTOR INHIBITORS FOR THE TREATMENT OF ANGIOGENIC DISEASES
ATE328602T1 (de) Kombinationspräparat zur behandlung des diabetes mellitus
GB0102408D0 (en) Chemical compounds
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ZA200103603B (en) Treatment of animal hides.
WO2000050023A8 (en) Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases
UA32314A (uk) Спосіб лікування некротичного панкреатиту
ECSP003458A (es) Compuestos para tratar la obesidad